A Study of LY3549492 in Healthy Participants

Part of paid clinical trials in Dallas, Texas.

Sponsor
Eli Lilly and Company
Study ID
NCT04758234
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • LY3549492 — DRUG
    Administered orally.
  • Placebo — DRUG
    Administered orally.

Study Details

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in healthy participants. The blood tests will be performed to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study includes two parts and will last up to approximately 76 days for each participant, including screening.

Key Dates

Start date
Feb 22, 2021
Status verified
Feb 2022
Primary completion
Jan 10, 2022
Completion
Jan 10, 2022

Study Design

Enrollment
54 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3549492 (Part A)
    LY3549492 administered orally as single ascending doses.
  • Experimental: LY3549492 (Part B)
    LY3549492 administered orally as multiple ascending doses.
  • Placebo Comparator: Placebo
    Placebo administered orally.

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through final follow-up at approximately Day 76 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Covance DallasDallasTexas75247-

Find similar trials in Dallas, TX

By research site
Covance Dallas· Dallas, TX

Related Studies